Thursday, July 26, 2012
Bio-Path Holdings Inc., of Houston, said it started enrolling patients in the fourth dosage cohort for its Phase I trial of lead candidate BP-100.1.01 (liposomal Grb-1), which is being evaluated as a systemic treatment for blood cancers, including acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.